TuHURA Biosciences, Inc./NV
TuHURA Biosciences, Inc./NV (HURA): 6 pipeline candidates · 1 upcoming catalyst · ~4 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
4.4 months
D/E 0.28 · 0% dilution
Lead: Phase 3
6 candidates
1 upcoming, next in ~2387d
N/A
A transparent, data-derived signal for TuHURA Biosciences, Inc./NVacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$141.4M
Cash
$6.3M
Quarterly Burn
$4.4M
Runway
4.4 mo
Revenue
$0
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (6 candidates)
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
87
Total value held
$20.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 4,148,456 | $7.4M |
| blackrock, inc. | 2,450,256 | $4.4M |
| geode capital management, llc | 986,922 | $1.8M |
| aqr capital management llc | 607,168 | $1.1M |
| state street corp | 512,913 | $918K |
| northern trust corp | 298,187 | $534K |
| vanguard fiduciary trust co | 287,133 | $514K |
| vanguard portfolio management llc | 253,641 | $454K |
| bank of new york mellon corp | 211,568 | $379K |
| cetera investment advisers | 140,244 | $251K |
Showing top 10 of 87 institutional holders of TuHURA Biosciences, Inc./NV. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in TuHURA Biosciences, Inc./NV's pipeline?
TuHURA Biosciences, Inc./NV (HURA) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is TuHURA Biosciences, Inc./NV's lead drug candidate?
TuHURA Biosciences, Inc./NV's most advanced tracked candidate is ifx-2.0 (Phase 3) for Advanced or metastatic Merkel cell carcinoma.
What is TuHURA Biosciences, Inc./NV's next catalyst?
TuHURA Biosciences, Inc./NV's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of IFx-Hu2.0 as an Adjunctive Ther" — expected December 30, 2032.
What is TuHURA Biosciences, Inc./NV's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, TuHURA Biosciences, Inc./NV has approximately 4.4 months of cash runway.
What is TuHURA Biosciences, Inc./NV's market capitalization?
TuHURA Biosciences, Inc./NV's market capitalization is approximately $141.4M.
Get the full picture on TuHURA Biosciences, Inc./NV
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.